The strategy of Cyto-Barr is focused on creating productive partnerships. Our role will be supportive, we assist in expertise, technology and supply of essential materials.
We are looking for industrial and/or NGO partners in order to implement our innovative methods, our lead reagents and expertise to find a cure for Nasopharyngeal cancer (NPC), Posttransplant Lymphoproliferative Disease (PTLD) and other EBV-linked cancer types.
Cyto-Barr owns patents for creating vaccines or antibody-based therapeutics targeting EBV-encoded surface antigens in cancers, like NPC and Hodgkin's Disease.
Cyto-Barr is developing innovative therapies targeting EBV in various EBV-associated cancer types, and is involved in phase-I clinical studies for the treatment of nasopharyngeal carcinoma (NPC), which is endemic in certain parts of Asia and Indonesia. In the Netherlands a phase-I therapeutic study was recently started and in Indonesia we are preparing such clinical studies. We also actively pursue screening studies for the early identification of NPC, in order to improve treatment options.